HitGen Ltd. of Chengdu has begun a multi-target, multi-year collaboration with LEO Pharma A/S, a Danish dermatology company. Using its very large DNA-encoded library of novel leads, HitGen will discover novel small molecule leads for multiple targets specified by LEO. HitGen has established discovery partnerships with major global pharmas, including Janssen, Merck, Pfizer and Scripps Research Institute. Under the terms of the LEO agreement, HitGen will receive an upfront payment and be eligible for milestones.
